{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T10:41:48.619037+00:00","company":{"ticker":"FEED","cik":1326706,"company_name":"ENvue Medical, Inc."},"pagination":{"limit":100,"returned":40,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Ultra Pain Products Inc.","detail":"supply","count":1,"first_seen":"2023-08-23T23:59:59+00:00","last_seen":"2023-08-23T23:59:59+00:00","evidence_fact_ids":[117054]},{"display_name":"Veranex, Inc.","detail":"other","count":1,"first_seen":"2024-03-28T23:59:59+00:00","last_seen":"2024-03-28T23:59:59+00:00","evidence_fact_ids":[64333]}],"lender":[{"display_name":"Alpha Capital Anstalt","detail":"loan","count":2,"first_seen":"2025-04-11T23:59:59+00:00","last_seen":"2025-04-11T23:59:59+00:00","evidence_fact_ids":[108669,108670]}],"ma_counterparty":[{"display_name":"ENvue Medical Holdings, Corp.","detail":"acquisition","count":1,"first_seen":"2025-02-14T23:59:59+00:00","last_seen":"2025-02-14T23:59:59+00:00","evidence_fact_ids":[95993]}]},"facts":[{"fact_type":"equity_issuance","fact_key":"3959c56e4860c569fd18521d1ab8ee9826ea7570","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2026-01-30T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":"the Required Holders agreed to amend the Certificate of Designations to remove the Floor Price in consideration of the holders of the Preferred Stock exercising","effective_date":"2026-01-30","item_codes_triggered":["3.03"],"purchaser":"Required Holders","security_type":"preferred_stock","shares_text":"exercising $2,500,000 of the Additional Investment Right"},"claim":"ENvue Medical, Inc. issued exercising $2,500,000 of the Additional Investment Right of preferred stock to Required Holders for the Required Holders agreed to amend the Certificate of Designations to remove the Floor Price in consideration of the holders of the Preferred Stock exercising.","evidence_excerpt":"On January 30, 2026, the Company entered into that certain Amendment Agreement (the \" Amendment Agreement \") with the Required Holders (as defined in the Amendment Agreement). Pursuant to the Amendment Agreement, the Required Holders agreed to amend the Certificate of Designations by filing a Certificate of Amendment (the \" Certificate of Amendment \") to the Certificate of Designations with the Secretary of State of the State of Delaware to remove the Floor Price (as defined in the Certificate of Designations) in consideration of the holders of the Preferred Stock exercising $2,500,000 of the Additional Investment Right (as such concept is described in the Securities Purchase Agreement by and between the Company and the holders of the Preferred Stock on July 18, 2025, and which such form of Securities Purchase Agreement is filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 22, 2025).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-004523","anchor_url":"https://secwatch.observer/filing/0001493152-26-004523#claim-3959c56e4860c569fd18521d1ab8ee9826ea7570","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315226004523/0001493152-26-004523-index.htm"},{"fact_type":"governance_change","fact_key":"84b74b9349a03dabf4b3016e47709c20c0770215","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2026-01-30T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Certificate of Amendment to Articles of Incorporation filed"},"claim":"ENvue Medical, Inc.: Certificate of Amendment to Articles of Incorporation filed.","evidence_excerpt":"matters described in Item 1.01 of this Current Report on Form 8-K related to the filing of the Certificate of Amendment is incorporated herein by reference.","confidence":0.4,"filing_url":"https://secwatch.observer/filing/0001493152-26-004523","anchor_url":"https://secwatch.observer/filing/0001493152-26-004523#claim-84b74b9349a03dabf4b3016e47709c20c0770215","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315226004523/0001493152-26-004523-index.htm"},{"fact_type":"governance_change","fact_key":"d5c1e69744ac9af833446c3ec211834573c411be","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-12-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-12","item_codes_triggered":["5.03"],"summary_text":"The Company changed its name from 'NanoVibronix, Inc.' to 'ENvue Medical, Inc.' via a Certificate of Amendment."},"claim":"ENvue Medical, Inc.: The Company changed its name from 'NanoVibronix, Inc.' to 'ENvue Medical, Inc.' via a Certificate of Amendment (effective 2025-12-12).","evidence_excerpt":"On December 8, 2025, the Company filed a Certificate of Amendment to ENvue Medical, Inc. (the “Company”) Certificate of Incorporation (the “Certificate of Amendment”) to change the name of the Company from “NanoVibronix, Inc.” to “ENvue Medical, Inc.” effective as of December 12, 2025 (the “Name Change”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-027380","anchor_url":"https://secwatch.observer/filing/0001493152-25-027380#claim-d5c1e69744ac9af833446c3ec211834573c411be","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225027380/0001493152-25-027380-index.htm"},{"fact_type":"auditor_change","fact_key":"4f5f713b82e359089dfd00027c711b2cc444786e","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-08-14T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global","disagreement_text":null,"effective_date":"2025-08-13","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ENvue Medical, Inc. engaged Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global as its auditor.","evidence_excerpt":"ppointment of New Independent Registered Public Accounting Firm On\nAugust 13, 2025, the Committee engaged Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (“ E&Y ”)\nas the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-023995","anchor_url":"https://secwatch.observer/filing/0001641172-25-023995#claim-4f5f713b82e359089dfd00027c711b2cc444786e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225023995/0001641172-25-023995-index.htm"},{"fact_type":"auditor_change","fact_key":"9d4dd98f188f03764d451e28ed1f70540188e2db","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-08-14T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Zwick CPA PLLC","disagreement_text":null,"effective_date":"2025-08-12","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ENvue Medical, Inc. dismissed Zwick CPA PLLC as its auditor.","evidence_excerpt":"On August 12, 2025, the Audit Committee of the Board of Directors (the “ Committee ”) of NanoVibronix, Inc. (the “ Company ”) approved the dismissal of Zwick CPA PLLC (“ Zwick ”) as the Company’s independent registered public accounting firm, effective as of the same date.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-023995","anchor_url":"https://secwatch.observer/filing/0001641172-25-023995#claim-9d4dd98f188f03764d451e28ed1f70540188e2db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225023995/0001641172-25-023995-index.htm"},{"fact_type":"governance_change","fact_key":"7e88510bea76e5075c397cb7291439f2ff6d7e13","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-08-08T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-08-11","item_codes_triggered":["5.03"],"summary_text":"1-for-10 reverse stock split of common stock"},"claim":"ENvue Medical, Inc.: 1-for-10 reverse stock split of common stock (effective 2025-08-11).","evidence_excerpt":"filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-10 reverse stock split","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-022751","anchor_url":"https://secwatch.observer/filing/0001641172-25-022751#claim-7e88510bea76e5075c397cb7291439f2ff6d7e13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225022751/0001641172-25-022751-index.htm"},{"fact_type":"governance_change","fact_key":"03a20580adb44aaccb71bc5c07384a42c1c03fc6","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-07-09T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-07-08","item_codes_triggered":["5.03"],"summary_text":"Certificate of Correction filed to fix a typographical error in the Floor Price definition in the Certificate of Designation for Series G Preferred Stock, changing it from $1.02 to $1.91."},"claim":"ENvue Medical, Inc.: Certificate of Correction filed to fix a typographical error in the Floor Price definition in the Certificate of Designation for Series G Preferred Stock, changing it from $1.02 to $1.91 (effective 2025-07-08).","evidence_excerpt":"On July 8, 2025, NanoVibronix, Inc. (the “ Company ”) filed with the Secretary of State of the State of Delaware, a certificate of correction (the “ Certificate of Correction ”) to the Company’s Certificate of Designation of the Preferences, Rights and Limitations of Series G Preferred Stock (the “ Certificate of Designations ”). The Certificate of Correction corrects an inadvertent typographical error in the definition of “Floor Price” in Section 1 of the Certificate of Designation, which should have been stated to be “$1.91” and was instead stated as “$1.02.”","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-018400","anchor_url":"https://secwatch.observer/filing/0001641172-25-018400#claim-03a20580adb44aaccb71bc5c07384a42c1c03fc6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225018400/0001641172-25-018400-index.htm"},{"fact_type":"executive_change","fact_key":"a30e9c5403","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-06-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-04","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Doron Besser was appointed as Chief Executive Officer at ENvue Medical, Inc..","evidence_excerpt":"the Board of Directors (the “ Board ”) of NanoVibronix, Inc. (the “ Company ”) appointed Doron Besser, M.D., a director of the Board and Chief Executive Officer and President of the Company’s wholly-owned subsidiary, ENvue Medical Holdings LLC (“ ENvue ”), as the Company’s Chief Executive Officer (“ CEO ”), effective as of the same date","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-013620","anchor_url":"https://secwatch.observer/filing/0001641172-25-013620#claim-a30e9c5403","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225013620/0001641172-25-013620-index.htm"},{"fact_type":"executive_change","fact_key":"fdb827bb82","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-06-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"retirement","effective_date":"2025-06-04","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Doron Besser","successor_named":true},"claim":"Brian Murphy resigned as Chief Executive Officer at ENvue Medical, Inc..","evidence_excerpt":"Brian Murphy resigned from the Company as its CEO due to Mr. Murphy’s retirement, effective as of the same date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-013620","anchor_url":"https://secwatch.observer/filing/0001641172-25-013620#claim-fdb827bb82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225013620/0001641172-25-013620-index.htm"},{"fact_type":"debt_financing","fact_key":"57a25202b82bf000ccc99eb4da2124f8d9331b9d","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-04-11T23:59:59+00:00","payload":{"counterparty":"Alpha Capital Anstalt","effective_date":"2025-04-11","event":"incurrence","instrument_type":"guarantee","interest_rate_text":"not specified","item_codes_triggered":["2.03"],"maturity_text":"not specified","principal_text":"all obligations and liabilities of ENvue under the Note"},"claim":"ENvue Medical, Inc. incurred guarantee of all obligations and liabilities of ENvue under the Note with Alpha Capital Anstalt at not specified maturing not specified.","evidence_excerpt":"In connection with ENvue’s issuance of the Note, on April 11, 2025, the Company entered into that certain Guaranty (the “ Guaranty ”) in favor of the Lender, pursuant to which the Company has agreed to guarantee to the Lender the payment of all obligations and liabilities of ENvue under the Note, including, without limitation, for principal, interest and any other amounts due and payable by ENvue under the Note (the “ Guaranteed Obligations ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-003717","anchor_url":"https://secwatch.observer/filing/0001641172-25-003717#claim-57a25202b82bf000ccc99eb4da2124f8d9331b9d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225003717/0001641172-25-003717-index.htm"},{"fact_type":"debt_financing","fact_key":"f25675a2bb301bdd75b8623403100bde58bf0cb3","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-04-11T23:59:59+00:00","payload":{"counterparty":"Alpha Capital Anstalt","effective_date":"2025-04-11","event":"incurrence","instrument_type":"loan","interest_rate_text":"8.0% per annum","item_codes_triggered":["2.03"],"maturity_text":"June 11, 2025","principal_text":"$360,000"},"claim":"ENvue Medical, Inc. incurred loan of $360,000 with Alpha Capital Anstalt at 8.0% per annum maturing June 11, 2025.","evidence_excerpt":"On April 11, 2025, ENvue Medical Holdings, Corp. (“ ENvue ”), a wholly-owned subsidiary of NanoVibronix, Inc. (the “ Company ”), issued a promissory note (the “ Note ”) to Alpha Capital Anstalt (the “ Lender ”) in the principal amount of $360,000 (the “ Principal Amount ”), together with all accrued interest thereon.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-003717","anchor_url":"https://secwatch.observer/filing/0001641172-25-003717#claim-f25675a2bb301bdd75b8623403100bde58bf0cb3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225003717/0001641172-25-003717-index.htm"},{"fact_type":"executive_change","fact_key":"29682fbb37","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-04-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Aurora Cassirer resigned as Director at ENvue Medical, Inc..","evidence_excerpt":"On April 1, 2025, Aurora Cassirer submitted her resignation as a member of the board of directors of NanoVibronix, Inc. (the “Company”), which resignation became effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-002556","anchor_url":"https://secwatch.observer/filing/0001641172-25-002556#claim-29682fbb37","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000164117225002556/0001641172-25-002556-index.htm"},{"fact_type":"governance_change","fact_key":"39479ee7c7a15ef2accebf3417a3b262b3cafe9f","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-03-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-03-13","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Amendment to effect a 1-for-11 reverse stock split of common stock."},"claim":"ENvue Medical, Inc.: Filed Certificate of Amendment to effect a 1-for-11 reverse stock split of common stock (effective 2025-03-13).","evidence_excerpt":"On March 12, 2025, NanoVibronix, Inc. (the “ Company ”) filed a Certificate of Amendment (the “ Certificate of Amendment ”) to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “ Certificate of Incorporation ”) with the Secretary of State of Delaware to effect a 1-for-11 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on March 13, 2025 (the “ Reverse Stock Split ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-010040","anchor_url":"https://secwatch.observer/filing/0001493152-25-010040#claim-39479ee7c7a15ef2accebf3417a3b262b3cafe9f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225010040/0001493152-25-010040-index.htm"},{"fact_type":"debt_financing","fact_key":"662758d3695dd054debea4c634e2fccc09327ef0","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"counterparty":null,"effective_date":"2025-02-13","event":"incurrence","instrument_type":"senior_notes","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":null},"claim":"ENvue Medical, Inc. incurred senior notes.","evidence_excerpt":"On February 13, 2025, pursuant to the Purchase Agreement, the Company issued the Debenture to the Investor.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-662758d3695dd054debea4c634e2fccc09327ef0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"ma_transaction","fact_key":"d2d191902f864753000475216f249ad140dafa13","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-02-14","consideration_text":"1,734,995 shares of common stock and 57,720 shares of Series X Non-Voting Convertible Preferred Stock","counterparty":"ENvue Medical Holdings, Corp.","effective_date":"2025-02-14","item_codes_triggered":["2.01"]},"claim":"ENvue Medical, Inc. completed an acquisition involving ENvue Medical Holdings, Corp. for 1,734,995 shares of common stock and 57,720 shares of Series X Non-Voting Convertible Preferred Stock (closed 2025-02-14).","evidence_excerpt":"and restated to, among other things, to change the name of the Surviving\nEntity to “ENvue Medical Holdings LLC.” In connection with the Merger Agreement, the Company issued (i) 1,734,995 shares\n(the “ Merger Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”)\nto the holders of ENvue, which such number of shares represented no more than","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-d2d191902f864753000475216f249ad140dafa13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"executive_change","fact_key":"9e821dede7","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Zeev Rotstein was appointed as Director at ENvue Medical, Inc..","evidence_excerpt":"on February 14, 2025, immediately after the Second Effective Time, Doron Besser, M.D., and Zeev Rotstein, M.D. were appointed to the Board as directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-9e821dede7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"executive_change","fact_key":"25eee7adde","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Doron Besser was appointed as Director at ENvue Medical, Inc..","evidence_excerpt":"on February 14, 2025, immediately after the Second Effective Time, Doron Besser, M.D., and Zeev Rotstein, M.D. were appointed to the Board as directors.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-25eee7adde","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"executive_change","fact_key":"6c3b77a9f0","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Ferguson resigned as Director at ENvue Medical, Inc..","evidence_excerpt":"on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-6c3b77a9f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"executive_change","fact_key":"f007074448","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Maria Schroeder resigned as Director at ENvue Medical, Inc..","evidence_excerpt":"on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-f007074448","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"executive_change","fact_key":"1689089e15","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Harold Jacob resigned as Director at ENvue Medical, Inc..","evidence_excerpt":"on February 14, 2025, immediately after the Second Effective Time, Harold Jacob, Maria Schroeder and Michael Ferguson resigned from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-006855","anchor_url":"https://secwatch.observer/filing/0001493152-25-006855#claim-1689089e15","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315225006855/0001493152-25-006855-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"07814aed6f98aa3cfddb70117d6ec2af7c1f3fb1","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2024-04-15T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2024-10-07","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 minimum closing bid price for at least 10 consecutive business days","notice_date":"2024-04-10","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 10, 2024, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq\nStock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30\nconsecutive business days between February 27, 2024, to April 9, 2024, the Company did not meet the minimum bid price of $1.00 per share\nrequired for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that\nthe Company will be provided with a compliance period of 180 calendar days, or until Oc","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-014611","anchor_url":"https://secwatch.observer/filing/0001493152-24-014611#claim-07814aed6f98aa3cfddb70117d6ec2af7c1f3fb1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224014611/0001493152-24-014611-index.htm"},{"fact_type":"material_agreement","fact_key":"41b66d0be92706d25d2a73f321aed7337feb8e7c","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement","agreement_type":"other","counterparty":"Veranex, Inc.","effective_date":"2024-03-22","item_codes_triggered":["1.01"],"value_text":"approximately $1.1 million"},"claim":"ENvue Medical, Inc. entered into Agreement with Veranex, Inc. valued at approximately $1.1 million (effective 2024-03-22).","evidence_excerpt":"On March 22, 2024, NanoVibronix, Inc., a New York corporation, (the “Company”), entered into a standalone services agreement (the “Agreement”), by and between the Company and Veranex, Inc., a Delaware corporation","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001493152-24-011629","anchor_url":"https://secwatch.observer/filing/0001493152-24-011629#claim-41b66d0be92706d25d2a73f321aed7337feb8e7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm"},{"fact_type":"auditor_change","fact_key":"e8f9346880a6fecfc588bd9f6765840b4623d33f","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Zwick CPA, PLLC","disagreement_text":null,"effective_date":"2023-12-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ENvue Medical, Inc. engaged Zwick CPA, PLLC as its auditor.","evidence_excerpt":"On December 7, 2023, the Company engaged Zwick CPA, PLLC (“Zwick”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044397","anchor_url":"https://secwatch.observer/filing/0001493152-23-044397#claim-e8f9346880a6fecfc588bd9f6765840b4623d33f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223044397/0001493152-23-044397-index.htm"},{"fact_type":"auditor_change","fact_key":"b089101a326cea0ddcc21c5abd096720f166961e","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-12-11T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Marcum LLP","disagreement_text":null,"effective_date":"2023-12-07","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ENvue Medical, Inc. dismissed Marcum LLP as its auditor.","evidence_excerpt":"On December 6, 2023, Nanovibronix, Inc. (the “Company”) dismissed Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm, effective as of December 7, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044397","anchor_url":"https://secwatch.observer/filing/0001493152-23-044397#claim-b089101a326cea0ddcc21c5abd096720f166961e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223044397/0001493152-23-044397-index.htm"},{"fact_type":"material_agreement","fact_key":"69e5e85026a0b49082dfdc6da620147888817a94","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-09-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"institutional investor","effective_date":"2023-08-30","item_codes_triggered":["1.01"],"value_text":"180,000 shares common stock, pre-funded warrants for 2,726,977 shares, A-1 Warrants for 2,906,977 sh"},"claim":"ENvue Medical, Inc. entered into Securities Purchase Agreement with institutional investor valued at 180,000 shares common stock, pre-funded warrants for 2,726,977 shares, A-1 Warrants for 2,906,977 sh (effective 2023-08-30).","evidence_excerpt":"On August 30, 2023, NanoVibronix, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the issuance and sale in a private placement (the “ Private Placement ”) of 180,000 shares (the “ Common Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”) , pre-funded warrants (“ Pre-Funded Warrants ”) to purchase up to 2,726,977 shares of common stock, with an exercise price of $0.0001 per share, A-1 Warrants (the “ A-1 Warrants ”) to purchase up to 2,906,977 shares of Common Stock, with an exercise price of $1.47 per share, and A-2 Warrants (the “ A-2 Warrants ” and together with the A-1 Warrants, the “ Warrants” ) to purchase up to 2,906,977 shares of Common Stock with an exercise price of $1.47 per share.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-031487","anchor_url":"https://secwatch.observer/filing/0001493152-23-031487#claim-69e5e85026a0b49082dfdc6da620147888817a94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223031487/0001493152-23-031487-index.htm"},{"fact_type":"material_agreement","fact_key":"e863584373bdd71f8f813800bff3bc99a5d44e5a","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-08-23T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended and Restated Distribution Agreement for private labeled products","agreement_type":"supply","counterparty":"Ultra Pain Products Inc.","effective_date":"2023-08-11","item_codes_triggered":["1.01"],"value_text":"Amendment to exclusive distribution agreement for PainShield and PainShield Plus devices; includes r"},"claim":"ENvue Medical, Inc. amended Amended and Restated Distribution Agreement for private labeled products with Ultra Pain Products Inc. valued at Amendment to exclusive distribution agreement for PainShield and PainShield Plus devices; includes r (effective 2023-08-11).","evidence_excerpt":"On August 22, 2023, NanoVibronix, Inc. (the “ Company ”), entered into a second amendment (the “Amendment”) to the Amended and Restated Distribution Agreement for private labeled products, dated December 10, 2020 (as amended by the Amendment, the “ Agreement ”), between the Company and Ultra Pain Products Inc. (“ UPPI ”), effective as of August 11, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-029969","anchor_url":"https://secwatch.observer/filing/0001493152-23-029969#claim-e863584373bdd71f8f813800bff3bc99a5d44e5a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223029969/0001493152-23-029969-index.htm"},{"fact_type":"shareholder_vote","fact_key":"43bc96ff7ff5134910f33b78d9a79ab007716ecc","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-21","outcome":"passed","proposal_text":"Approval of an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposals 1 and 2.","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"2,380","votes_against":"82,423","votes_for":"744,905","votes_withheld":"0"}]},"claim":"ENvue Medical, Inc. shareholders approved Approval of an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposals 1 and 2. at the 2023-06-21 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 3. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 744,905 82,423 2,380 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-23-022031","anchor_url":"https://secwatch.observer/filing/0001493152-23-022031#claim-43bc96ff7ff5134910f33b78d9a79ab007716ecc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223022031/0001493152-23-022031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7c0fd13ae34a6a99d7e995f9dd8cdea8d505168b","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-21","outcome":"passed","proposal_text":"Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"2,547","votes_against":"153,422","votes_for":"673,739","votes_withheld":"0"}]},"claim":"ENvue Medical, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-21 meeting.","evidence_excerpt":"The Company’s stockholders approved Proposal 2. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 673,739 153,422 2,547 0","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-23-022031","anchor_url":"https://secwatch.observer/filing/0001493152-23-022031#claim-7c0fd13ae34a6a99d7e995f9dd8cdea8d505168b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223022031/0001493152-23-022031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"593775e21e84391287e8905097e7b51ad608cc33","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-06-21T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-21","outcome":"passed","proposal_text":"Election of eight nominees to serve on the Board for a term of one year or until their respective successors are elected and qualified.","proposal_type":"director_election","results":[{"broker_non_votes":"547,860","subject":"Aurora Cassirer","votes_abstain":"0","votes_against":"0","votes_for":"260,498","votes_withheld":"21,350"},{"broker_non_votes":"547,860","subject":"Christopher Fashek","votes_abstain":"0","votes_against":"0","votes_for":"270,506","votes_withheld":"11,342"},{"broker_non_votes":"547,860","subject":"Michael Ferguson","votes_abstain":"0","votes_against":"0","votes_for":"243,563","votes_withheld":"38,285"},{"broker_non_votes":"547,860","subject":"Martin Goldstein, M.D.","votes_abstain":"0","votes_against":"0","votes_for":"270,607","votes_withheld":"11,241"},{"broker_non_votes":"547,860","subject":"Harold Jacob, M.D.","votes_abstain":"0","votes_against":"0","votes_for":"270,624","votes_withheld":"11,224"},{"broker_non_votes":"547,860","subject":"Thomas Mika","votes_abstain":"0","votes_against":"0","votes_for":"237,243","votes_withheld":"44,605"},{"broker_non_votes":"547,860","subject":"Brian Murphy","votes_abstain":"0","votes_against":"0","votes_for":"267,992","votes_withheld":"13,856"},{"broker_non_votes":"547,860","subject":"Maria Schroeder","votes_abstain":"0","votes_against":"0","votes_for":"270,274","votes_withheld":"11,574"}]},"claim":"ENvue Medical, Inc. shareholders approved Election of eight nominees to serve on the Board for a term of one year or until their respective successors are elected and qualified. at the 2023-06-21 meeting.","evidence_excerpt":"On June 21, 2023, NanoVibronix, Inc. (the “Company”), held its 2023 annual meeting of stockholders (the “Annual Meeting”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-23-022031","anchor_url":"https://secwatch.observer/filing/0001493152-23-022031#claim-593775e21e84391287e8905097e7b51ad608cc33","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223022031/0001493152-23-022031-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"66c979e4f90c6f5aaf542252f8c330106368b4d5","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-05-25T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2023-07-07","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$2.5 million","notice_date":"2023-05-23","notice_type":"deficiency_notice","plan_due_date":"2023-07-07","raw_rule_text":"NASDAQ Listing Rule 5550(b)(1)","reported_value":"$2.2 million","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 23, 2023, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the NASDAQ\nStock Market (“NASDAQ”) indicating that the Company no longer complies with the minimum stockholders’ equity requirement\nunder NASDAQ Listing Rule 5550(b)(1) for continued listing on The NASDAQ Capital Market because the Company’s stockholders’\nequity of approximately $2.2 million as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31,\n2023, is below the required minimum of $2.5 million, and as of May 22, 2023, the Company does not meet t","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-019096","anchor_url":"https://secwatch.observer/filing/0001493152-23-019096#claim-66c979e4f90c6f5aaf542252f8c330106368b4d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223019096/0001493152-23-019096-index.htm"},{"fact_type":"governance_change","fact_key":"27d8830365e47c9317370302a137e07ef8e8ad7e","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2023-02-08T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-02-08","item_codes_triggered":["5.03"],"summary_text":"Reverse stock split of common stock at a 1-for-20 ratio via Certificate of Amendment to Amended and Restated Certificate of Incorporation"},"claim":"ENvue Medical, Inc.: Reverse stock split of common stock at a 1-for-20 ratio via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2023-02-08).","evidence_excerpt":"On February 8, 2023, NanoVibronix, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 4:05 p.m. (Delaware time) on February 8, 2023 (the “Reverse Stock Split”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-003953","anchor_url":"https://secwatch.observer/filing/0001493152-23-003953#claim-27d8830365e47c9317370302a137e07ef8e8ad7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315223003953/0001493152-23-003953-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5930ed3ce945d8498b690dd36cf96b4d751d3906","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Adjournment of the Annual Meeting to a later date, if necessary, to permit further solicitation and vote of proxies","proposal_type":"other","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"1,025,729,488","votes_against":"1,483,069,491","votes_for":"10,300,095,777","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders approved Adjournment of the Annual Meeting to a later date, if necessary, to permit further solicitation and vote of proxies.","evidence_excerpt":"Proposal 7. A proposal to approve an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of Proposals 1-5 (the “Adjournment Proposal”). The Company’s stockholders approved Proposal 7. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 10,300,095,777 1,483,069,491 1,025,729,488 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-5930ed3ce945d8498b690dd36cf96b4d751d3906","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"2fafd3a89a3f2dd6c3ccfa4b90a5dcfa9f945a54","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-31","outcome":"passed","proposal_text":"Ratification of Marcum LLP as the independent registered public accounting firm for fiscal year ending December 31, 2022","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"70,890","votes_against":"359,883","votes_for":"12,365,983","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders approved Ratification of Marcum LLP as the independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-12-31 meeting.","evidence_excerpt":"Proposal 6. A proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The Company’s stockholders approved Proposal 6. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 12,365,983 359,883 70,890 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-2fafd3a89a3f2dd6c3ccfa4b90a5dcfa9f945a54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d377dc9276d4f4666e870fa26e35fcac8274fa2d","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Amendment to the 2014 Plan to increase the aggregate number of shares reserved for issuance by 1,518,000 shares to a total of 4,864,286 shares","proposal_type":"equity_plan","results":[{"broker_non_votes":"9,139,369","subject":null,"votes_abstain":"601,182","votes_against":"1,232,591","votes_for":"1,823,614","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders approved Amendment to the 2014 Plan to increase the aggregate number of shares reserved for issuance by 1,518,000 shares to a total of 4,864,286 shares.","evidence_excerpt":"Proposal 5. A proposal to approve an amendment to the 2014 Plan to increase the aggregate number of shares of common stock of the Company reserved for issuance under the 2014 Plan by 1,518,000 shares to a total of 4,864,286 shares. The Company’s stockholders approved Proposal 5. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 1,823,614 1,232,591 601,182 9,139,369","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-d377dc9276d4f4666e870fa26e35fcac8274fa2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"789761e3429443fe3da9ff67bb9934b639d2f85b","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"failed","proposal_text":"Amendment to increase authorized shares of common stock from 40,000,000 to 45,000,000","proposal_type":"charter_amendment","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"324,026","votes_against":"3,355,281","votes_for":"9,117,449","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders rejected Amendment to increase authorized shares of common stock from 40,000,000 to 45,000,000.","evidence_excerpt":"Proposal 4. A proposal to approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock of the Company from 40,000,000 to 45,000,000 shares. The Company’s stockholders did not approve Proposal 4. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 9,117,449 3,355,281 324,026 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-789761e3429443fe3da9ff67bb9934b639d2f85b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d3da4fd66ed959ce3dddc54cf9bf1f04a38319cf","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Reverse stock split of common stock at a ratio in the range of 1-for-2 to 1-for-50, with ratio to be determined by the Board","proposal_type":"reverse_split","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"618,754,541","votes_against":"2,494,061,218","votes_for":"9,696,078,997","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders approved Reverse stock split of common stock at a ratio in the range of 1-for-2 to 1-for-50, with ratio to be determined by the Board.","evidence_excerpt":"Proposal 3. A proposal to approve an amendment to the Company’s Certificate of Incorporation to effect, at the discretion of the Company’s Board but prior to the six-month anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Company’s Common Stock, at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined by the Board in its discretion and included in a public announcement (the “Reverse Stock Split Proposal”). The Company’s stockholders approved Proposal 3. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 9,696,078,997 2,494,061,218 618,754,541 0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-d3da4fd66ed959ce3dddc54cf9bf1f04a38319cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0aa6e017d97370effce00c67e99e48f74040346a","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"failed","proposal_text":"Amendment to classify the board structure into three classes with three-year terms","proposal_type":"charter_amendment","results":[{"broker_non_votes":"9,139,369","subject":null,"votes_abstain":"353,719","votes_against":"1,187,392","votes_for":"2,116,276","votes_withheld":null}]},"claim":"ENvue Medical, Inc. shareholders rejected Amendment to classify the board structure into three classes with three-year terms.","evidence_excerpt":"Proposal 2. A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to classify the structure of the Board to be designated Class I, Class II, and Class III with directors in each class to be elected for three-year terms. The Company’s stockholders did not approve Proposal 2. The results of the voting were as follows: For Against Abstentions Broker Non-Votes 2,116,276 1,187,392 353,719 9,139,369","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-0aa6e017d97370effce00c67e99e48f74040346a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a1103f4a80b0641bdb5504edb1dbff04a76df31d","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-12-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of eight nominees to serve on the board of directors for a one-year term","proposal_type":"director_election","results":[{"broker_non_votes":"9,139,369","subject":"Aurora Cassirer","votes_abstain":null,"votes_against":null,"votes_for":"3,388,415","votes_withheld":"268,972"},{"broker_non_votes":"9,139,369","subject":"Christopher Fashek","votes_abstain":null,"votes_against":null,"votes_for":"3,403,556","votes_withheld":"253,831"},{"broker_non_votes":"9,139,369","subject":"Michael Ferguson","votes_abstain":null,"votes_against":null,"votes_for":"3,240,236","votes_withheld":"417,151"},{"broker_non_votes":"9,139,369","subject":"Martin Goldstein, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,369,339","votes_withheld":"288,048"},{"broker_non_votes":"9,139,369","subject":"Harold Jacob, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,298,119","votes_withheld":"359,268"},{"broker_non_votes":"9,139,369","subject":"Thomas Mika","votes_abstain":null,"votes_against":null,"votes_for":"3,035,409","votes_withheld":"621,978"},{"broker_non_votes":"9,139,369","subject":"Brian Murphy","votes_abstain":null,"votes_against":null,"votes_for":"3,310,077","votes_withheld":"347,310"},{"broker_non_votes":"9,139,369","subject":"Maria Schroeder","votes_abstain":null,"votes_against":null,"votes_for":"3,406,884","votes_withheld":"250,503"}]},"claim":"ENvue Medical, Inc. shareholders approved Election of eight nominees to serve on the board of directors for a one-year term.","evidence_excerpt":"Proposal 1. A proposal to elect eight nominees to serve on the Company’s board of directors (the “Board”), for a term of one year or until their respective successors are elected and qualified, for which the following are nominees: Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder. All nominees were elected to serve as directors. The results of the voting were as follows: Nominees Votes For Withheld Broker Non-Votes Aurora Cassirer 3,388,415 268,972 9,139,369 Christopher Fashek 3,403,556 253,831 9,139,369 Michael Ferguson 3,240,236 417,151 9,139,369 Martin Goldstein, M.D. 3,369,339 288,048 9,139,369 Harold Jacob, M.D. 3,298,119 359,268 9,139,369 Thomas Mika 3,035,409 621,978 9,139,369 Brian Murphy 3,310,077 347,310 9,139,369 Maria Schroeder 3,406,884 250,503 9,139,369","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-22-035628","anchor_url":"https://secwatch.observer/filing/0001493152-22-035628#claim-a1103f4a80b0641bdb5504edb1dbff04a76df31d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222035628/0001493152-22-035628-index.htm"},{"fact_type":"executive_change","fact_key":"a8284a4164","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-01-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Maria Schroeder was appointed as Director at ENvue Medical, Inc..","evidence_excerpt":"appointed Aurora Cassirer and Maria Schroeder to the Board to serve as independent directors, effective as of January 13, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-001217","anchor_url":"https://secwatch.observer/filing/0001493152-22-001217#claim-a8284a4164","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222001217/0001493152-22-001217-index.htm"},{"fact_type":"executive_change","fact_key":"9677f0cb16","cik":1326706,"ticker":"FEED","company_name":"ENvue Medical, Inc.","filed_at":"2022-01-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-13","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Aurora Cassirer was appointed as Director at ENvue Medical, Inc..","evidence_excerpt":"appointed Aurora Cassirer and Maria Schroeder to the Board to serve as independent directors, effective as of January 13, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-001217","anchor_url":"https://secwatch.observer/filing/0001493152-22-001217#claim-9677f0cb16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315222001217/0001493152-22-001217-index.htm"}]}